Greater than two in 5 (42%) or 57.4 million adults beneath 65 with personal insurance coverage could possibly be eligible beneath scientific standards for GLP-1 medicine used to deal with individuals with sort 2 diabetes, weight problems, or extra weight and weight-related well being points, in keeping with a brand new KFF evaluation.
Although solely about 3% of adults with employer protection had a prescription in 2022, demand for and spending on GLP-1 medicine has grown and will proceed to develop. Given the steep prices and excessive demand for these medicine, employers and insurers could proceed to impose extra restrictive eligibility requirements for protection than the scientific indications set by the Meals and Drug Administration.
The total evaluation and different knowledge on well being prices can be found on the Peterson-KFF Well being System Tracker, an internet data hub devoted to monitoring and assessing the efficiency of the U.S. well being system.